Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00157703
Status:
COMPLETED
Last Update Posted:
2008-12-16
First Post:
2005-09-08
Brief Title:
G207 Followed by Radiation Therapy in Malignant Glioma
Sponsor:
MediGene
Organization:
MediGene
Study Overview
Official Title:
A Staged Phase 1 Study of the Treatment of Malignant Glioma With G207 a Genetically Engineered HSV-1 Followed by Radiation Therapy
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label single site study to evaluate the safety and tolerability of intratumoral administration of G207 followed by treatment with radiation therapy in patients with recurrentprogressive malignant glioma
This study is a two stage phase 1 study in which a de-escalating dosing scheme will be used ie the first patients will receive the higher dose and if excessive toxicity occurs the dose will be reduced for the following patients The purpose of the dose de-escalation phase is to find the best safe dose of G207
In the first stage of the study treatment with G207 will be followed by focal radiation therapy on the following day and in the second stage treatment with G207 will be followed by gamma knife surgery also on the following day
All patients will return to the clinic 28 days and 3 6 9 and 12 months after G207 administration at which time clinical assessments will be performed and will be followed for safety and survival at clinic visits or by telephone every 3 months for up to 2 additional years and annually thereafter
This study is a two stage phase 1 study in which a de-escalating dosing scheme will be used ie the first patients will receive the higher dose and if excessive toxicity occurs the dose will be reduced for the following patients The purpose of the dose de-escalation phase is to find the best safe dose of G207
In the first stage of the study treatment with G207 will be followed by focal radiation therapy on the following day and in the second stage treatment with G207 will be followed by gamma knife surgery also on the following day
All patients will return to the clinic 28 days and 3 6 9 and 12 months after G207 administration at which time clinical assessments will be performed and will be followed for safety and survival at clinic visits or by telephone every 3 months for up to 2 additional years and annually thereafter
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None